Fig. 2: EB-42168 demonstrates full inhibition of LRRK2 pSer935 in cells overexpressing G2019S-LRRK2 at concentrations that show no inhibition in WT-LRRK2 overexpressing cells.
From: G2019S selective LRRK2 kinase inhibitor abrogates mitochondrial DNA damage
a Representative western blot of WT-LRRK2 or G2019S-LRRK2 cells treated with DMSO, 10 nM, 100 nM or 1 µM MLi-2 for 2 h and assessed for LRRK2 pSer935 and full-length LRRK2. b Representative western blot of WT-LRRK2 or G2019S-LRRK2 cells treated with DMSO, 10 nM, 100 nM or 1 µM EB-42168 for 2 h and assessed for LRRK2 pSer935 and full-length LRRK2. c Quantification of western blots demonstrate a 70%, 90% and 95% decrease, respectively, in LRRK2 pSer935 levels with increasing concentration of MLi-2 in WT-LRRK2 expressing cells. Quantification of western blots demonstrate an 80%, 96% and 97% decrease respectively in LRRK2 pSer935 levels with increasing concentration of MLi-2 in G2019S-LRRK2 expressing cells. d Quantification of western blots demonstrate no change in LRRK2 pSer935 levels with EB-42168 treatment in WT-LRRK2 expressing cells. Quantification of western blots demonstrate a 65% and 95% decrease respectively in LRRK2 pSer935 levels with 100 nM and 1 µM of EB-42168 in G2019S-LRRK2 expressing cells. Data are presented as mean ± SEM. n = 3 replicates. (*p < 0.0001 determined by two-way ANOVA). GS-LRRK2 G2019S-LRRK2, WT-LRRK2 wild-type LRRK2, ns non-significant.
